drugset / Trial / NCT01327235

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

NCT01327235

Phase 2 Completed 336 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.

Timeline

Start
2011-03
Primary completion
2014-04
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 40 mg
Subject Endostar Protein / enzyme biologic 45 mg Other
Subject Endostar Protein / enzyme biologic 60 mg Other